Roivant Sciences Ltd. (ROIV): Price and Financial Metrics


Roivant Sciences Ltd. (ROIV): $4.04

-0.06 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ROIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ROIV Stock Price Chart Interactive Chart >

Price chart for ROIV

ROIV Price/Volume Stats

Current price $4.04 52-week high $16.76
Prev. close $4.10 52-week low $2.52
Day low $3.90 Volume 1,167,600
Day high $4.18 Avg. volume 442,769
50-day MA $4.09 Dividend yield N/A
200-day MA $0.00 Market Cap 2.80B

Roivant Sciences Ltd. (ROIV) Company Bio


Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.


ROIV Latest News Stream


Event/Time News Detail
Loading, please wait...

ROIV Latest Social Stream


Loading social stream, please wait...

View Full ROIV Social Stream

Latest ROIV News From Around the Web

Below are the latest news stories about Roivant Sciences Ltd that investors may wish to consider to help them evaluate ROIV as an investment opportunity.

Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $14.00. The company's shares closed last Monday at $7.20, close to its 52-week low of $5.80. According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 39.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $14.50 average price target.

Howard Kim on TipRanks | February 15, 2022

Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update

Roivant’s newly launched subsidiary, Hemavant, entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001, a potential first-in-class small molecule modulator of splicing factor 3B subunit 1 (SF3B1) for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromesDermavant has hired key commercial leadership positions in preparation for launch of tapinarof for psoriasis, subject to the FDA’s appr

Yahoo | February 14, 2022

Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022

Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ETRoivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium and Cowen Healthcare Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live confe

Yahoo | February 7, 2022

Roivant Sciences (ROIV) Presents At B. Riley Securities Virtual Oncology Conference - Slideshow

The following slide deck was published by Roivant Sciences Ltd. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 28, 2022

Roivant to Present at Upcoming Investor Conferences

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ETSVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET A live webcast of each presentation will be available under “Events & Presentations” on the Investors section of th

Yahoo | January 25, 2022

Read More 'ROIV' Stories Here

ROIV Price Returns

1-mo 9.49%
3-mo -35.77%
6-mo -39.06%
1-year N/A
3-year N/A
5-year N/A
YTD -59.92%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5787 seconds.